BR112013015974A2 - uso de nifuratel para tratar infecções causadas por espécies de clostridium - Google Patents

uso de nifuratel para tratar infecções causadas por espécies de clostridium

Info

Publication number
BR112013015974A2
BR112013015974A2 BR112013015974A BR112013015974A BR112013015974A2 BR 112013015974 A2 BR112013015974 A2 BR 112013015974A2 BR 112013015974 A BR112013015974 A BR 112013015974A BR 112013015974 A BR112013015974 A BR 112013015974A BR 112013015974 A2 BR112013015974 A2 BR 112013015974A2
Authority
BR
Brazil
Prior art keywords
nifuratel
infections caused
treat infections
clostridium species
clostridium
Prior art date
Application number
BR112013015974A
Other languages
English (en)
Inventor
Bulgheroni Anna
Mailland Federico
Iob Giuliana
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of BR112013015974A2 publication Critical patent/BR112013015974A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013015974A 2011-02-22 2012-01-19 uso de nifuratel para tratar infecções causadas por espécies de clostridium BR112013015974A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11155283A EP2491929A1 (en) 2011-02-22 2011-02-22 Use of Nifuratel to treat infections caused by Clostridium species
PCT/EP2012/050759 WO2012113594A1 (en) 2011-02-22 2012-01-19 Use of nifuratel to treat infections caused by clostridium species

Publications (1)

Publication Number Publication Date
BR112013015974A2 true BR112013015974A2 (pt) 2018-06-05

Family

ID=44059064

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015974A BR112013015974A2 (pt) 2011-02-22 2012-01-19 uso de nifuratel para tratar infecções causadas por espécies de clostridium

Country Status (24)

Country Link
EP (2) EP2491929A1 (pt)
KR (1) KR20140021525A (pt)
CN (1) CN103384523B (pt)
AR (1) AR085266A1 (pt)
BR (1) BR112013015974A2 (pt)
CL (1) CL2013002098A1 (pt)
CY (1) CY1116210T1 (pt)
DK (1) DK2678015T3 (pt)
EA (1) EA025645B1 (pt)
ES (1) ES2529210T3 (pt)
GE (1) GEP20156264B (pt)
HK (1) HK1187553A1 (pt)
HR (1) HRP20150141T1 (pt)
ME (1) ME02056B (pt)
MX (1) MX341213B (pt)
PL (1) PL2678015T3 (pt)
PT (1) PT2678015E (pt)
RS (1) RS53739B1 (pt)
SI (1) SI2678015T1 (pt)
SM (1) SMT201500039B (pt)
TW (1) TWI536989B (pt)
UA (1) UA113159C2 (pt)
UY (1) UY33915A (pt)
WO (1) WO2012113594A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102885793B (zh) * 2012-10-15 2014-08-20 山东罗欣药业股份有限公司 一种硝呋太尔组合物片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000255A1 (en) * 2001-06-25 2003-01-03 Essential Therapeutics, Inc. Novel nitrofuran-containing heterocyclic compounds and uses thereof
EP2243482A1 (en) 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species

Also Published As

Publication number Publication date
MX2013009686A (es) 2013-12-06
MX341213B (es) 2016-08-11
WO2012113594A1 (en) 2012-08-30
EP2678015A1 (en) 2014-01-01
EP2678015B1 (en) 2014-11-26
EP2491929A1 (en) 2012-08-29
HK1187553A1 (en) 2014-04-11
TW201309292A (zh) 2013-03-01
KR20140021525A (ko) 2014-02-20
CY1116210T1 (el) 2017-02-08
ME02056B (me) 2015-05-20
RS53739B1 (en) 2015-06-30
UY33915A (es) 2012-04-30
DK2678015T3 (en) 2015-01-26
GEP20156264B (en) 2015-03-25
TWI536989B (zh) 2016-06-11
SI2678015T1 (sl) 2015-03-31
UA113159C2 (xx) 2016-12-26
AR085266A1 (es) 2013-09-18
CN103384523B (zh) 2015-04-29
CL2013002098A1 (es) 2014-06-06
ES2529210T3 (es) 2015-02-18
EA025645B1 (ru) 2017-01-30
CN103384523A (zh) 2013-11-06
PT2678015E (pt) 2015-02-10
PL2678015T3 (pl) 2015-04-30
HRP20150141T1 (en) 2015-03-13
SMT201500039B (it) 2015-03-05
EA201370179A1 (ru) 2014-03-31

Similar Documents

Publication Publication Date Title
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
CO6811868A2 (es) Combinaciones de principios activos
BR112014016798A8 (pt) método de uso de aditivos tensoativos
BR112013033720A2 (pt) método para tratar eczema
BR112014006324A2 (pt) método para tratar hcv
BR112014007959A2 (pt) mecanismos para comunicação de dispositivo para dispositivo
CR20130677A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
CR20140034A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
DK2667849T3 (da) Brusende sammensætning i fast form til vaginal anvendelse til behandling af vaginale infektioner
BR112014011900A2 (pt) um método de purificação de anticorpo
BR112014013034A2 (pt) método para produzir um anticorpo
BR112014003352A2 (pt) métodos para fabricação de construções estruturais
BR112014009785A2 (pt) método para tratar ou reduzir efp
CL2014003059A1 (es) Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose.
CO6791617A2 (es) Combinaciones de compuestos activos
BR112014010997A2 (pt) processo para o preparo de ß-glicosídeos de c-arila
BR112014008691A2 (pt) anticorpos para cd1d
BR112013033851A2 (pt) método para formar sevoflurano
BR112014020597A2 (pt) compostos para tratar infecção por parvovírus
CR20130603A (es) Compuestos novedosos como inhibidores de diacilglicerol
BR112013032825A2 (pt) redutores de água de variação intermediária (mrwr) para concretos
CO6821942A2 (es) Combinaciones de compuestos activos
BR112014032593A2 (pt) método para purificar silício
BR112013015533A2 (pt) processo para produzir óxido de olefina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.